Speaking of novel therapeutic opportunities, is it worth mentioning that almost a quarter (3/13, 23%) of HER2-discrepant cases from our casuistry showed an increase in ALNs from a 0/1+ to a 1+ or 2+ (FISH negative) IHC score, belonging to the so-called HER2-low BC category. The gene discussed is ERBB2; the disease is breast cancer.